©The Author(s) 2015.
World J Crit Care Med. May 4, 2015; 4(2): 139-151
Published online May 4, 2015. doi: 10.5492/wjccm.v4.i2.139
Published online May 4, 2015. doi: 10.5492/wjccm.v4.i2.139
Table 9 Implications of medications for the pregnant critically ill patient
| Indication/class | Specific drug | FDA3 | Comments1 | Indication/class | Specific drug | FDA3 | Comments1 |
| Sedative | Propofol | B | Anticoagulant | Enoxaparin | B | ||
| Midazolam | D | Heparin | C | ||||
| Lorazepam | D | Risk (1st and 3rd trimesters) | Fondaparinux | B | |||
| Dexmedetomidine | C | Argatroban | B | ||||
| Analgesic | Morphine | C | Risk (3rd trimester) | Corticosteroid | Methylprednisolone | C | |
| Fentanyl | C | Risk (3rd trimester) | Hydrocortisone | C | Data suggest risk | ||
| Hydromorphone | C | Risk (3rd trimester) | Antifungal/antiviral | Voriconazole | D | ||
| Delirium | Quetiapine | C | Risk (1st and 3rd trimesters) | Fluconazole | D | Data suggest risk if > 400 mg/d | |
| Haloperidol | C | Micafungin | C | ||||
| Pulmonary hypertension | Epoprostenol | B | Amphotericin | B | |||
| Treprostinil | B | Acyclovir | B | ||||
| Iloprost | C | Antibiotic | Azithromycin | B | |||
| Bronchodilator | Tiotropium | C | Aztreonam | B | |||
| Ipratropium | B | Cefazolin | B | ||||
| Albuterol | B | Cefepime | B | ||||
| Levalbuterol | C | Cefoxitin | B | ||||
| Vasoactive | Epinephrine | C | Data suggest risk | Ceftriaxone | B | ||
| Norepinephrine | C | Data suggest risk | Ciprofloxacin | C | Data suggest low risk | ||
| Vasopressin | C | Clindamycin | B | ||||
| Phenylephrine | C | Data suggest risk | Linezolid | C | |||
| Dopamine | C | Meropenem | B | ||||
| Dobutamine | B | Metronidazole | B | Data suggest low risk | |||
| Milrinone | C | Moxifloxacin | C | Data suggest low risk | |||
| Antiarrhythmic | Diltiazem | C | Data suggest low risk | Piperacillin/tazobactam | B | ||
| Amiodarone | D | Data suggest risk | Vancomycin | C | |||
| Digoxin | C | Anti-seizure2 | Levetiracetam | C | |||
| Antihypertensive | Labetalol | C | Data suggest low risk | Phenytoin | D | ||
| Esmolol | C | Paralytic | Rocuronium | C | |||
| Hydralazine | C | Risk (3rd trimester) | Cisatracurium | B | |||
| Magnesium sulfate | D | Vecuronium | C | ||||
| Nitroglycerin | C | Data suggest low risk | Succinylcholine | C | |||
| Sodium nitroprusside | C | Data suggest risk | |||||
| ACE-inhibitors | D | Data suggest risk (2nd and 3rd trimesters) | |||||
| Diuretic | Furosemide | C | Data suggest low risk | ||||
| Mannitol | C | ||||||
| GI/antiemetic | Pantoprazole | B | Data suggest low risk | ||||
| Famotidine | B | ||||||
| Ondansetron | B | ||||||
| Metoclopramide | B | ||||||
| Erythromycin (non-estolate) | B |
- Citation: Erstad BL. Designing drug regimens for special intensive care unit populations. World J Crit Care Med 2015; 4(2): 139-151
- URL: https://www.wjgnet.com/2220-3141/full/v4/i2/139.htm
- DOI: https://dx.doi.org/10.5492/wjccm.v4.i2.139